Hubbard Thomas J E, Isaac Anna T, Cui Alice, Cutress Ramsey I, Dave Rajiv, Ellis Katy, Fields Jo, Halliday Suzanne, Hu Jennifer, Potter Shelley, Chagla Leena, Cox Karina, Holcombe Christopher
Faculty of Health and Life Sciences, University of Exeter, Exeter.
School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland.
Int J Surg Protoc. 2024 Feb 15;28(1):37-42. doi: 10.1097/SP9.0000000000000021. eCollection 2024 Mar.
Breast pain accounts for 20-40% of new referrals to breast units in the UK and these patients have a very low risk of breast cancer. Patients have previously been assessed in resource-intensive, cancer-exclusion, one stop clinics, which are now failing to meet government targets due to excessive demand. UK Breast units are increasingly piloting Breast Pain-only Pathways (BPP) to assess these patients, and there is no consensus for the optimal pathway. The aim of this prospective multicentre study is to assess the safety and patient satisfaction of different BPPs to inform future BPP design and implementation.
All UK breast units will be invited to join the ASPIRE study between January 2023 and December 2023. Units with a BPP are invited to submit their pathway for evaluation; and those without a BPP who see patients with breast pain-only in a one stop clinics setting are also invited to join the study to evaluate the traditional pathway model concurrently. Patient satisfaction assessments will be collected after their initial consultation and patient outcomes, including subsequent cancer diagnosis, will be followed up at 12 months to determine if they have cancer diagnosis after discharge to assess pathway safety.
在英国，乳房疼痛占乳腺科新转诊患者的20%-40%，这些患者患乳腺癌的风险非常低。此前，患者在资源密集型、癌症排除的一站式诊所接受评估，由于需求过多，这些诊所现在未能达到政府目标。英国乳腺科越来越多地试行仅针对乳房疼痛的诊疗路径（BPP）来评估这些患者，对于最佳诊疗路径尚无共识。这项前瞻性多中心研究的目的是评估不同BPP的安全性和患者满意度，为未来BPP的设计和实施提供依据。
2023年1月至2023年12月期间，将邀请所有英国乳腺科加入ASPIRE研究。有BPP的科室被邀请提交其诊疗路径进行评估；那些在一站式诊所仅诊治乳房疼痛患者且没有BPP的科室也被邀请加入研究，同时评估传统诊疗路径模式。在患者初次咨询后收集患者满意度评估结果，并在12个月时对患者结局进行随访，包括后续癌症诊断情况，以确定出院后是否被诊断为癌症，从而评估诊疗路径的安全性。
